Illumina leads the DNA sequencing market with next-generation sequencing platforms, controlling ~80% global share and reducing genome sequencing costs to ~$200.
summary: Illumina โ dominant DNA sequencing technology company, controlling ~80% of the global sequencing market with next-generation sequencing (NGS) platforms.
read_when:
Researching genomics and DNA sequencing technology
Studying the Grail acquisition and antitrust challenges
Analyzing the transition from research to clinical sequencing
Exploring personalized medicine and liquid biopsy
Illumina
ๅๅฒๆถ้ด็บฟ
1998: Founded in San Diego by Larry Bock, John Stuelpnagel, and others
2007: Goes public, rapid growth in genomics research market
2014: NovaSeq launches โ highest-throughput sequencer at the time
2018: NovaSeq 6000 reduces genome sequencing cost to ~$200
2021: Acquires Grail (cancer blood test company) for $7.1B
2022: EU orders Illumina to divest Grail (antitrust)
2024: Completes Grail divestiture, refocuses on core sequencing
ๅไธๆจกๅผ
DNA sequencing instruments, consumables (flow cells, reagents), and bioinformatics. 'Razor and blades' model โ sells instruments at competitive prices, generates recurring revenue from high-margin consumables. NovaSeq and NextSeq platforms dominate research and clinical markets.
ๆคๅๆฒณๅๆ
~80% market share in DNA sequencing โ near monopoly. Installed base of instruments creates locked-in consumables revenue. Technology lead in accuracy and throughput. Network effects from bioinformatics ecosystem.
ๅ ณ้ฎๆฐๆฎ
Founded: 1998, San Diego, California
Revenue 2023: ~$4.5B
Market Share: ~80% of NGS market
Employees: ~10,000
Genome Sequencing Cost: ~$200 (vs. $100M in 2001)
ๆ่ถฃไบๅฎ
Illumina's technology has reduced the cost of sequencing a human genome from ~$100 million in 2001 to about $200 today โ faster than Moore's Law.
The Grail acquisition and forced divestiture became one of the most consequential antitrust cases in biotech history โ the EU literally forced Illumina to undo a $7.1B deal.
